Spirax Group PLC (OTCPK:SPXSF)
$ 91.1 (0%) Market Cap: 6.79 Bil Enterprise Value: 7.58 Bil PE Ratio: 31.87 PB Ratio: 4.25 GF Score: 89/100

Full Year 2025 Spirax Group PLC Earnings Call Transcript

Mar 10, 2026 / 09:30AM GMT
Release Date Price: $101.2

Key Points

Positve
  • Spirax Group PLC (SPXSY) achieved a 5% organic sales growth and a 6% increase in adjusted operating profit, outperforming industrial production (IP).
  • The company maintained a strong group margin of 20%, up 30 basis points, by focusing on pricing and cost discipline.
  • The restructuring program completed in 2025 resulted in annualized savings of GBP40 million, which are being reinvested in future growth.
  • Watson-Marlow division saw a 6% sales growth with margins up 160 basis points to 26.2%, driven by strong demand in Biopharm and Process Industries.
  • Cash conversion improved to 89%, with leverage reducing to 1.5 times, reflecting strong cash discipline.
Negative
  • Geopolitical tensions and tariff volatility negatively impacted large project demand in China and Korea, leading to weak demand in these regions.
  • Currency movements had a negative impact of 3% on sales and 4% on operating profit, posing a challenge to financial performance.
  • The macroeconomic environment remained weak and volatile, with global IP excluding China at only 1.7%, below historic averages.
  • The effective tax rate increased to 27.3%, reflecting a higher profit mix and the absence of one-off benefits from the prior year.
  • The restructuring program incurred a GBP40 million cost, with GBP22 million spent in 2025 and the remaining GBP11 million expected to be spent in 2026.
Nimesh Patel
Spirax Group PLC - Group Chief Executive Officer, Executive Director

Hello, and thank you for joining us for this presentation of Spirax Group's results. I'm Nimesh Patel, Group CEO, and I'm joined by Louisa Burdett, our Group CFO. I'm going to start by summarizing our 2025 performance. Today's results demonstrate our ability to deliver good organic growth at high margins by focusing on the operational priorities that are within our control and despite the weak macroeconomic environment that endured through the year.

Looking to our organic measures, we outperformed IP with group sales growth of 5%, and adjusted operating profit grew 6%, and all three businesses delivered growth and improved margins. Group margin was 20%, up 30 basis points as we maintained pricing and cost discipline and manage the headwinds from FX and tariff impacts while also investing in future growth. So a good set of results, slightly ahead of expectations. I would like to thank my colleagues around the world for their commitment to achieving these results through advancing the execution of our strategy.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot